Fact-checked by Grok 2 weeks ago

Integra LifeSciences

Integra LifeSciences Holdings Corporation is a global medical technology company headquartered in , that develops, manufactures, and markets innovative surgical devices and solutions primarily focused on , regenerative tissue technologies, and . Founded in 1989 by Dr. Richard Caruso through the acquisition of an engineered collagen technology platform for tissue repair and regeneration, the company has grown to employ approximately 4,400 people worldwide as of December 2024 and trades on the under the ticker symbol IART. Its mission centers on expanding access to technologies that enable the body to regenerate damaged or diseased tissue, thereby improving patient outcomes and setting new standards in surgical care. The company's portfolio spans two main segments: Codman Specialty Surgical, which provides devices, instruments, and systems for , neuromonitoring, neurotrauma, and critical care, including solutions for dural repair, cerebral spinal fluid management, and treatment of conditions like brain tumors, , , and hemorrhagic ; and Tissue Technologies, which offers regenerative products for repair, peripheral and reconstruction, acute and chronic wound management, burns, hernia repair, and plastic/. Integra is dedicated to limiting uncertainty for surgeons, allowing them to focus on delivering optimal patient care through a broad range of high-quality, reliable medical devices. In recent years, Integra has continued to innovate, launching initiatives such as its global platform, Integra Institute, in January 2025, and reporting 5% organic revenue growth in the third quarter of 2025, reflecting strong demand for its products amid a of approximately $1.2 billion as of October 2025. With a of entering the market in , including the divestiture of its Extremity Orthopedics business in 2020, and expanding through internal development and strategic acquisitions, Integra remains a leader in transforming surgical practices and .

Company Overview

Founding and Mission

Integra LifeSciences was founded on June 19, 1989, by Dr. Richard E. Caruso, Ph.D., a scientist with expertise in biomaterials who held a B.S. from , an M.S.B.A. from , and a Ph.D. from the London School of Economics. Caruso established the company to advance , drawing on his background to commercialize innovative repair solutions. At its inception, Integra acquired a pioneering collagen-based artificial skin technology, originally developed by Professor Ioannis V. Yannas of MIT and Dr. John F. Burke of Harvard Medical School and the Shriners Hospitals for Children Burn Institute. This technology, a bilayer matrix of bovine and chondroitin-6-sulfate combined with a silastic , was licensed from the Harvard-MIT of Sciences and after its prior rights were held by Marion Laboratories. The acquisition formed the basis for Integra's early product development, targeting dermal regeneration without scarring. The company's core mission centered on developing technologies that harness the body's natural regenerative capabilities to treat severe burns, wounds, and other tissue damage, with a vision to enable the to repair many of its own damaged or diseased tissues. This focus on regenerative solutions for burns and wounds aimed to improve patient outcomes by promoting true tissue regrowth rather than mere coverage or . Initially headquartered at 311 Enterprise Drive in Plainsboro, , Integra was funded through offerings to support its efforts. Over time, this foundational approach evolved to encompass broader applications in and .

Current Operations and Market Position

Integra LifeSciences Holdings Corporation is headquartered in , and maintains a global network of manufacturing and facilities to support its operations in the industry. In the , key manufacturing sites are located in states including (near ), California, , , , , , and . Internationally, the company operates facilities in —such as in , , , and —and in , including an assembly site in , , enabling efficient production and across regions. These operations facilitate product to over 120 countries through direct sales, distributors, and wholesalers, with significant contributions from the (approximately 74% of 2024 revenues), (about 10%), (around 11%), and Rest of World (about 5%). The company's revenue is primarily derived from two main segments: Codman Specialty Surgical, which encompasses , surgical instruments, and solutions, and Tissue Technologies, focused on regenerative and reconstructive applications. In the third quarter of 2025, Codman Specialty Surgical accounted for approximately 73% of total revenues at $292.6 million, while Tissue Technologies contributed about 27% at $109.5 million, reflecting the company's strong positioning in specialized surgical markets. Overall, for 2025, Integra anticipates full-year revenues between $1.62 billion and $1.64 billion, with the third quarter achieving $402.1 million in reported revenues, marking a 5.6% increase year-over-year and 5.0% amid ongoing optimizations. As a mid-cap firm traded on under the ticker IART, Integra LifeSciences had a of approximately $910 million as of November 2025, underscoring its established yet competitive standing in the sector. The company employs about 4,400 full- and part-time workers worldwide as of late 2024, with a distributed across the U.S. (70%), (20%), and (9%). Integra demonstrates a commitment to innovation through investments, allocating 7.2% of its 2024 revenues—equating to $115.4 million—to R&D activities that support advancements in surgical technologies.

Historical Development

Early Years and Initial Innovations

Integra LifeSciences, founded in 1989 by Richard Caruso with a vision to advance tissue regeneration technologies, quickly pursued key acquisitions to bolster its portfolio. In June 1991, the company acquired Colla-Tec, Inc., a focused on collagen-based care products, from Inc. Two months later, Integra secured additional care assets and technology from Marion Merrell Dow's Wound Care Division, enhancing its capabilities in scaffolds essential for tissue repair applications. Building on licensed artificial skin technology originally developed by researchers Ioannis Yannas and John Burke at Harvard-MIT, Integra advanced the , a bilayer matrix designed to promote dermal regeneration in severe wounds. The company continued and expanded clinical trials initiated earlier under , evaluating the template's efficacy in small patient cohorts with deep partial- to full-thickness burns where autograft availability was limited. These efforts culminated in the template's first human applications for burn treatments in the early 1990s, demonstrating the potential for scarless regeneration by integrating with the patient's own cells to form neodermis. To fund commercialization, Integra went public in August through a reverse merger with Telios Pharmaceuticals, listing on under the ticker IART and raising capital to support product scaling and further . However, the pre-IPO period was marked by significant financial challenges, as substantial investments in led to net losses exceeding $27 million cumulatively in and , with sales reaching only $8.7 million in despite growing interest in the company's innovations. These losses reflected the high costs of clinical validation and scale-up in the nascent field of regenerative technologies during the early .

Post-IPO Expansion

Following its in 1995, Integra LifeSciences experienced significant growth catalyzed by the U.S. Food and Drug Administration's (FDA) approval of the Integra Dermal Regeneration Template in 1996, the company's first major commercial product for treating severe burns and full-thickness skin injuries. This approval marked a pivotal milestone, enabling the product to address a critical need in wound care and , and contributed to a surge in annual revenues to $13.1 million in 1996, up from lower pre-approval levels driven primarily by research grants and limited sales. The template's success laid the foundation for broader commercialization efforts, as it was the first FDA-approved device to regenerate dermal tissue, positioning Integra as an innovator in . In the late , Integra expanded into the market with the development and launch of dural repair products, including the DuraGen Dural Graft Matrix, which received FDA clearance in 1999 for repairing dural defects during cranial and spinal surgeries. This move diversified the company's portfolio beyond wound care into neurotrauma and reconstructive applications, supported by the 1999 acquisition of NeuroCare Group, which enhanced Integra's neurosurgical offerings and established its initial direct sales presence in . By leveraging these advancements, Integra strengthened its position in high-growth surgical segments, with products accounting for a growing share of revenues as demand for minimally invasive repair solutions increased. Integra's international expansion began in earnest with market entry into in 1998 through distribution agreements and regulatory approvals, followed by penetration into during the early via partnerships and the establishment of its first overseas in via the NeuroCare acquisition. A key 1999 with , a Johnson & Johnson , facilitated global distribution of the Dermal Regeneration Template, accelerating adoption outside the U.S. and contributing to revenue diversification. This international push complemented domestic growth, as evidenced by revenues rising from $71.6 million in 2000 to $732.1 million by 2010, fueled by organic product development, expanded sales infrastructure, and targeted small acquisitions that integrated complementary technologies without major disruptions. The period's emphasis on scaling operations and solidified Integra's transition from a specialized biotech firm to a multinational leader.

Products and Technologies

Regenerative and Wound Reconstruction

Integra LifeSciences' regenerative and reconstruction portfolio centers on advanced biomaterials designed to facilitate repair and regeneration, particularly for dermal and defects. These products leverage bioengineered matrices to support cellular infiltration, vascularization, and neodermis formation, addressing challenges in care, wounds, and reconstructive procedures. The company's offerings in this area stem from decades of innovation in collagen-based technologies, emphasizing acellular scaffolds that minimize and promote natural healing processes. A cornerstone product is the Integra Dermal Regeneration Template (DRT), a bilayer matrix consisting of an inner layer of ultra-pure bovine cross-linked with chondroitin-6-sulfate and an outer layer that serves as a temporary . This structure provides a scaffold for migration and neodermis development, with the silicone layer protecting the wound bed while controlling moisture and heat loss. The FDA approved DRT in for the treatment of life-threatening full-thickness burns where autograft donor sites are insufficient, and indications were later expanded to include scar contracture release and full-thickness skin loss from or surgical excision, as well as chronic wounds such as ulcers. Complementing DRT, SurgiMend PRS is an acellular dermal matrix derived from fetal bovine dermis, offering a non-crosslinked, native scaffold rich in Type III to support reinforcement and integration. It is indicated for plastic and , including post-mastectomy and , where it reinforces weakened tissue and aids in defect closure without eliciting significant . The matrix hydrates quickly and maintains structural integrity during implantation, facilitating surgeon handling in operating room settings. The portfolio was enhanced by the 2021 acquisition of ACell, Inc., which introduced urinary bladder matrix (UBM) technologies like MicroMatrix and Gentrix products. MicroMatrix consists of porcine UBM particulates that can be applied as a powder or paste to conform to irregular beds, promoting rapid and shifting the wound microenvironment toward a pro-healing state by increasing M2 activity. It is suitable for partial- and full-thickness wounds, pressure ulcers, and surgical sites. Gentrix Surgical Matrix, also porcine UBM-based, serves as a resorbable graft for soft tissue reinforcement in ventral repairs and other defects, remodeling into site-specific tissue over time. These UBM products expand options for managing complex, tunneled wounds and contaminated sites. Clinical studies demonstrate robust outcomes for these technologies, with DRT achieving mean graft take rates of 76-88% in and reconstructive applications, and median rates exceeding 95% in multicenter trials involving over 3,600 patients. For instance, in excision cases, DRT supported autograft take rates of 87-94%, reducing donor site needs and hospitalization durations compared to traditional methods. SurgiMend PRS has shown low complication rates in cohorts, with effective tissue incorporation in 80-90% of implants. Overall, the regenerative portfolio is a key component of the Tissue Technologies segment, which accounts for approximately 30% of Integra's revenues and reported $109.5 million in the third quarter of 2025.

Neurosurgery and Tissue Ablation

Integra LifeSciences offers a range of specialized products for and tissue , focusing on dural repair, precise tissue removal, and cerebrospinal fluid (CSF) management to support and spinal procedures such as tumor resection and repair. These solutions emphasize , precision, and minimally invasive techniques to improve patient outcomes in complex neurosurgical environments. DuraGen Dural Graft Matrix and Durepair Dura Regeneration Matrix are collagen-based dural substitutes designed for repairing dural defects following neurosurgical interventions like tumor resection or . DuraGen, made from ultra-pure derived from bovine deep flexor , serves as an absorbable onlay graft that promotes rapid cellular infiltration and neodural formation within two weeks, with full resorption and replacement by native dura occurring in 6-8 weeks. Clinical studies involving over 1,400 patients have demonstrated low complication rates, including 0% response, 1.9% , and 2.1% CSF leakage, making it suitable for suture-less cranial and spinal closures. Durepair, derived from fetal bovine without cross-linking, provides a strong suturable graft with tensile strength approximately twice that of human dura, enabling onlay or direct repair while conforming to native tissue for effective barrier restoration. Both products are indicated for repair and sourced from U.S.-compliant cattle to minimize risks like . The CUSA Clarity Ultrasonic Surgical Aspirator represents a key advancement in ablation for , enabling precise fragmentation, emulsification, and of soft and hard tissues such as tumors, fibrous structures, and bone. This integrated system combines a console, handpiece, and tips operating at frequencies like 23 kHz for challenging procedures and 36 kHz for general use, allowing surgeons to debulk quickly while preserving surrounding structures. Originally cleared for neurosurgical applications, it received U.S. FDA 510(k) clearance in November 2025 for cardiac surgeries, including and valve repair, thereby expanding its utility beyond neural to enhance precision in cardiothoracic procedures. Integra's Codman portfolio, acquired in 2017, bolsters with tools for CSF management, including ventricular s and external ventricular drainage (EVD) systems. The Codman Ventricular facilitates temporary insertion into ventricles for CSF drainage in conditions like , while the Bactiseal EVD incorporates impregnation to reduce risks during external drainage. These silicone-based devices support by enabling controlled CSF diversion and monitoring, often integrated with irrigation capabilities for maintaining patency. The segment demonstrates strong market leadership, with organic revenue growth of 13.3% in the third quarter of 2025, driven by demand for dural repair, , and CSF solutions used extensively in cranial and spinal procedures worldwide.

Surgical Instruments and Other Solutions

Integra LifeSciences offers a diverse portfolio of surgical instruments through brands such as Miltex and Ruggles-Redmond, focusing on reusable and disposable tools designed for , orthopedics, and procedures. Miltex instruments, crafted from high-quality , include , hemostats, , and needle holders that support cutting, grasping, clamping, and dissecting functions across multiple specialties. Similarly, Ruggles-Redmond provides specialized handheld instruments like curettes, retractors, and rongeurs, emphasizing durability and for operating rooms and centers in orthopedic and general applications. These tools prioritize minimally invasive techniques, enabling surgeons to perform procedures with reduced and improved efficiency. In the ear, nose, and throat (ENT) domain, Integra's Acclarent products feature balloon sinuplasty devices that facilitate sinus interventions by dilating blocked passageways to promote mucus drainage and alleviate chronic sinusitis symptoms. The RELIEVA SPINPLUS and SPINPLUS NAV systems, for instance, offer navigated access and single-handed control for precise balloon dilation and irrigation during endoscopic procedures. Acquired from Johnson & Johnson in 2024, these devices expand Integra's capabilities in minimally invasive ENT solutions. For orthopedic applications, Integra provides implants such as the Salto Talaris Total Ankle System, a fixed-bearing that replicates natural ankle to treat end-stage ankle through reconstruction. Acquired in 2015, this system includes components for stable tibial and talar fixation, supporting flexion and extension movements while improving pain and functional outcomes in clinical studies. This segment, encompassing surgical instruments, ENT devices, and orthopedic implants, generated approximately $340 million in revenue in 2024, representing about 21% of Integra's total $1.61 billion, with ongoing emphasis on innovations for minimally invasive procedures projected to sustain similar contributions in 2025.

Acquisitions and Business Growth

Key Acquisitions Timeline

Integra LifeSciences has pursued growth through targeted acquisitions, completing a total of 16 by September 2025, the majority located in the United States. In 1991, the company acquired Colla-Tec, Inc., from Marion Merrell Dow, Inc., incorporating advanced collagen-based technologies for wound care applications. In 2017, Integra acquired the Codman Neurosurgery business from Johnson & Johnson for $1.045 billion in cash, adding a portfolio of dural repair substitutes, cerebrospinal fluid management devices, and other neurosurgical products. This deal significantly expanded Integra's presence in , contributing to subsequent growth in that segment. In 2021, Integra completed the acquisition of ACell, Inc., for an upfront cash payment of $300 million subject to adjustments, plus up to $100 million in contingent earn-out payments, bolstering its regenerative wound care offerings with MatriStem urinary matrix technologies. In 2024, the company acquired Acclarent, Inc., from for $275 million in cash, marking its entry into the ear, nose, and throat market with balloon-based sinuplasty and related surgical intervention devices.

Strategic Impacts and Integrations

Integra LifeSciences has strategically transitioned from a primary focus on its foundational product, the Integra Dermal Regeneration Template, to a diversified multi-segment leader in medical technology through a series of acquisitions since 2017. This approach has broadened the company's portfolio across , , orthopedics, and tissue technologies, fostering revenue diversification and enhanced market positioning in high-growth surgical areas. Acquisitions have been instrumental in this evolution, contributing substantially to overall growth—such as approximately 83% of the 19.8% revenue increase in 2017—and enabling Integra to capture larger addressable markets estimated at over $10 billion globally. The 2017 acquisition and integration of the Codman Neurosurgery business marked a pivotal expansion, adding more than 1,000 products to Integra's offerings and transforming its capabilities into a dominant segment. This move significantly boosted revenue, with the Codman Specialty Surgical segment growing to represent about 71% of total company by , reaching $1,143.6 million—a substantial increase from pre-acquisition levels where Integra's contributions were under $100 million annually. Within two years post-integration, the segment experienced robust growth, including 3.3% organic expansion in 2019, driven by synergies in cranial and spinal products that solidified Integra's leadership in the $3 billion global market. Subsequent acquisitions like ACell in 2021 have further diversified the regenerative and orthopedics segments within the Tissue Technologies division, incorporating proprietary technologies for advanced wound care and surgical reconstruction. ACell's integration expanded Integra's regenerative portfolio, complementing existing ortho solutions and contributing to the segment's $466.9 million in 2024 revenue, while supporting broader initiatives. These enhancements have driven approximately 5% revenue growth in early 2025, with regenerative and orthopedics areas accounting for key contributions amid strong demand for complex tissue repair products—though exact segmental attribution remains integrated within overall Tissue Technologies performance. Despite these successes, acquisition integrations have presented notable challenges, including elevated costs for operational alignment and . For instance, integration expenses reached $33.6 million in 2024 for recent deals, while efforts to meet EU Medical Device Regulation requirements incurred $44.6 million in costs, alongside FDA warning letters and product recalls that temporarily disrupted supply chains and growth momentum. These hurdles have occasionally strained margins and required substantial investments in quality systems, underscoring the complexities of scaling a multi-segment portfolio.

Regulatory and Legal Challenges

FDA Inspections and Product Recalls

In 2023, Integra LifeSciences initiated a voluntary recall of all products manufactured at its , facility between March 1, 2018, and May 22, 2023, due to identified issues with in-process and finished goods that posed contamination risks, including potential bacterial endotoxin exposure in collagen-based devices such as the Durepair dural repair matrix. The recall encompassed tissue repair products used in and wound care, leading to a temporary halt in production at the site to address deficiencies. This action followed an FDA from March to May 2023, which revealed quality system failures, including inadequate investigation of out-of-specification endotoxin results, insufficient corrective and preventive actions (CAPA) for prior complaints such as cases linked to Durepair, and improper storage of non-sterile devices alongside sterile ones. The FDA issued a warning letter on July 17, 2023, citing violations of current (CGMP) requirements under 21 CFR Part 820, and required third-party audits with certifications extending through 2026. Subsequent regulatory scrutiny intensified with a December 19, 2024, FDA warning letter addressing violations identified during inspections at three facilities: Mansfield, Massachusetts; Plainsboro, New Jersey; and Princeton, New Jersey. The letter highlighted deficiencies in sterile processing, such as inadequate prevention of contamination, unvalidated process changes for sterilization and bioburden testing, and failures in finished device acceptance procedures for products including cranial perforators, cottonoid patties, and collagen-based wound care devices. Integra responded with remediation plans, including process revalidations and CAPA enhancements, though the FDA noted that the adequacy of these measures remained under review with completion timelines extending to 2027. Into 2025, Integra continued remediation efforts amid ongoing FDA inspections, achieving partial clearances at two facilities not subject to the prior warning letters, while facing persistent issues in wound care product lines, including additional recalls for sterility concerns in items like MediHoney gel, MicroMyst applicators, Codman Disposable Perforators (linked to 10 injuries from weld defects), and Extended Tip Applicators (due to potential non-sterility and high endotoxin levels). These developments prompted temporary production pauses beyond the initial Boston shutdown, contributing to supply chain disruptions that delayed availability of regenerative tissue products and affected neurosurgical procedures reliant on dural substitutes. The 2023 Boston recall alone resulted in an estimated $60 million revenue impact for that year due to the manufacturing stoppage, underscoring broader operational challenges from regulatory non-compliance.

Litigation and Securities Issues

In 2023, Integra LifeSciences faced a class-action lawsuit filed in the U.S. District Court for the District of , alleging that the company and its executives misled investors regarding the progress of manufacturing remediation efforts at its facility following FDA inspections. The suit, covering the period from 11, 2019, to May 22, 2023, claimed violations of Sections 10(b) and 20(a) of the , particularly after the company's May 23, 2023, announcement of a voluntary recall of all products manufactured at the site since 2018, which triggered a 20.7% drop in share price that day. As of November 2025, the case remains ongoing, with a consolidated complaint filed in September 2024 and a partial motion to dismiss granted in June 2025, allowing plaintiffs to amend their claims. In January 2025, a whistleblower lawsuit was filed in the U.S. District Court for the District of by former Chief Quality Officer Susan Krause against Integra LifeSciences, alleging retaliation under the Minnesota Whistleblower Act for raising concerns about product safety and manufacturing quality. Krause claimed she faced pressure from executives to approve and ship faulty products despite known compliance issues, including relabeling non-conforming items and certifying unsafe dural repair products, leading to her termination in 2024. The suit also includes claims of , citing hostile treatment such as yelling and ; as of September 2025, the court denied Integra's motion to transfer the case and partially granted a motion to dismiss non-whistleblower claims, allowing the core allegations to proceed. Shareholder investigations into potential breaches of fiduciary duty by Integra's board intensified in 2024 and 2025, prompted by declines linked to ongoing recalls and regulatory scrutiny, including the 20% share drop in May 2023. These probes, led by firms such as Kaskela Law and Grabar Law, examined whether directors failed to oversee with FDA standards, resulting in suits like Leverett v. Anderson et al. filed in May 2025 in the U.S. District Court for the District of (stayed as of September 2025). The alleges that executives overstated remediation in 2024 disclosures, leading to further and losses exceeding $2 billion from the high. As of November 2025, multiple federal suits remain active against Integra LifeSciences, including the securities and derivative claims in , as well as the whistleblower case in , with no final resolutions reported. These proceedings highlight ongoing scrutiny of the company's disclosures and internal controls amid quality control challenges.

References

  1. [1]
    COMPANY PROFILE | Integra LifeSciences Holdings Corporation
    Integra is a leader in neurosurgery, offering a broad portfolio of devices, instruments and systems used in neurosurgery, neuromonitoring, neurotrauma, and ...
  2. [2]
    Who We Are - Integra LifeSciences
    Integra LifeSciences (Integra) was founded in 1989 based on a vision to expand access to promising technology that enables the body to regenerate damaged or ...
  3. [3]
    Celebrating 35 Years of Innovation - Integra LifeSciences
    Jul 29, 2024 · Dr. Richard Caruso acquired this technology and founded Integra LifeSciences in 1989. Dr. Caruso had a vision to expand access to ...
  4. [4]
    Integra LifeSciences Corporation
    We are the global leader in neurosurgery, offering a broad portfolio of products and solutions for dural access and repair, cerebral spinal fluid management ...Our Company · Contact Us · Careers · Nerve & Tendon
  5. [5]
    INVESTOR OVERVIEW | Integra LifeSciences Holdings Corporation
    Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best ...Company profile · Events & Presentations · Press Releases · Contact Us
  6. [6]
    Integra LifeSciences Holdings Corp Company Profile - GlobalData
    Integra LifeSciences Holdings Corp (Integra) is a medical technology company that develops and manufactures engineered collagen-based product lines.
  7. [7]
    Integra LifeSciences Reports Third Quarter 2025 Financial Results
    5% organic growth, with demand remaining strong · Delivered $0.54 adjusted EPS, above expectations · Revising 2025 guidance to reflect third quarter revenue and ...
  8. [8]
    Integra LifeSciences Holding 2025 Company Profile - PitchBook
    Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy.
  9. [9]
    [PDF] Integra LifeSciences Holdings Corporation, through internal product ...
    Integra was founded in 1989 and over the next decade developed technologies and a product portfolio directed toward tissue regeneration. In 1999, we entered the ...
  10. [10]
    Integra LifeSciences Launches New Corporate Identity
    Oct 14, 2010 · Founded in 1989, Integra has grown into a world leader in medical devices. Its orthopedic products include devices and implants for spine, foot ...
  11. [11]
    Integra LifeSciences Celebrates 20th Anniversary - Investor Overview
    Jun 19, 2009 · ... Integra LifeSciences Holdings Corporation (Nasdaq:IART) is celebrating its 20th anniversary. Officially founded on June 19, 1989, Integra ...
  12. [12]
    Integra LifeSciences Announces the Passing of Dr. Richard Caruso ...
    Aug 16, 2022 · Caruso founded Integra LifeSciences in 1989 with a vision that the human body could be enabled to regenerate many of its own damaged or diseased ...
  13. [13]
    Richard E. Caruso: books, biography, latest update - Amazon.com
    CARUSO, Ph.D. founded Integra LifeSciences Corporation ("Integra") in 1989 (www.integra-ls.com). Dr. Caruso currently serves as the ...
  14. [14]
    Shared "Uncommon" Vision Leads to Birth of Regenerative Medicine
    Nov 21, 2006 · Caruso learned that this technology, known as Integra, had been licensed by MIT to pharmaceutical company Marion Laboratories in Kansas City, ...
  15. [15]
    [PDF] INTEGRA LIFESCIENCES HOLDINGS CORPORATION
    Integra. NeuroSciences accounted for 64% of total revenues in 2000 and 68% of total revenues during the first three months of 2001. Our goal is to become a ...
  16. [16]
    [PDF] securities and exchange commission - Integra LifeSciences
    Dec 31, 2000 · To date, we have funded our operations primarily through private and public offerings of equity securities, product revenues, research and ...
  17. [17]
    [PDF] Form 10-K for Integra Lifesciences Holdings Corp filed 02/25/2025
    Feb 25, 2025 · Expected volatilities are based on the historical volatility of the Company's stock price. The expected life of stock options is estimated ...
  18. [18]
    [PDF] Integra LifeSciences Reports Third Quarter 2025 Financial Results
    Oct 30, 2025 · Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year. Third ...
  19. [19]
    Integra LifeSciences Holdings Corporation (IART) - Yahoo Finance
    Based in Princeton, New Jersey, Integra is a medical device company that develops and markets devices for use in neurosurgery, nerve repair, and skin and wound ...
  20. [20]
    Integra LifeSciences Holdings Corporation - Encyclopedia.com
    Integra LifeSciences Holdings Corporation FOUNDING IN 1989 CARUSO JOINS COMPANY FULL TIME: 1992 REVERSE STOCK SPLIT: 1998 PRINCIPAL SUBSIDIARIES PRINCIPAL ...Missing: initial private
  21. [21]
    25-Year History of Integra® Dermal Regeneration Template
    Mar 21, 2021 · Today, IDRT remains the only FDA-approved regenerative skin technology for the treatment of life-threatening burns, and its indications not ...Missing: based artificial MIT
  22. [22]
    The Innovation That Changed Complex Burn Wound Care Forever
    Initially known as “artificial skin,” the invention is now called Integra Dermal Regeneration Template (IDRT).Missing: Harvard | Show results with:Harvard
  23. [23]
    Integra LifeSciences Holdings (IART) Stock Price & Overview
    Healthcare. IPO Date Aug 16, 1995. Employees 4,396. Stock Exchange NASDAQ. Ticker Symbol IART. Website https://www.integralife.com · Full Company Profile ...
  24. [24]
    Integra LifeSciences History: Founding, Timeline, and Milestones
    Company founded. Headquarters. Plainsboro, NJ. Company headquarter. Founders. Richard Caruso. Company founders.<|control11|><|separator|>
  25. [25]
    P900033 - Premarket Approval (PMA) - FDA
    INTEGRA DERMAL REGENERATION TEMPLATE. Generic Name, Dressing, wound and burn, interactive. Applicant, Integra LifeSciences Corp. 105 MORGAN LN. PLAINSBORO, NJ ...
  26. [26]
    [PDF] 1998 Annual Report - Integra LifeSciences
    Integra LifeSciences Corporation (Nasdaq: IART), founded in 1989, develops, manufactures and markets medical devices, implants and biomaterials.
  27. [27]
    [PDF] integra lifesciences - accessdata.fda.gov
    Jul 6, 1999 · DuraGen™ Dural Graft Matrix is an absorbable implant for repair of dura mater. DuraGen ™ is an easy to handle, soft, white, pliable, nonfriable, ...
  28. [28]
    [PDF] 2000 Annual Report
    The terms “we”, “our”, “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings ... net operating losses, which expire between 2002 and 2010.
  29. [29]
    Integra LifeSciences (IART) - Revenue - Companies Market Cap
    Current and historical revenue charts for Integra LifeSciences. As of November 2025 Integra LifeSciences's TTM revenue is of $1.62 Billion USD.
  30. [30]
    Integra LifeSciences Reports Fourth Quarter and Full Year 2010 ...
    Total revenues for the fourth quarter were $194.1 million, reflecting an increase of $10.6 million, or 6%, over the fourth quarter of 2009. Total revenues in ...Missing: 2000 $50 $500
  31. [31]
    Wound Reconstruction and Care - Integralife.com
    Integra offers a portfolio of engineered collagen products, such as Integra® Dermal Regeneration Template and Integra® Bilayer Wound Matrix. Learn More.
  32. [32]
    Integra® Dermal Regeneration Template - Integralife.com
    Integra Dermal Regeneration Template (DRT) is the first and only FDA-approved skin substitute for the treatment of third degree burns and scar contracture.
  33. [33]
    Integra LifeSciences Announces FDA Approval to Market INTEGRA ...
    The INTEGRA Template was first approved in 1996 for the treatment of life-threatening thermal injuries where sufficient autograft is not available at the time.Missing: date | Show results with:date
  34. [34]
    SurgiMend® PRS Collagen Matrix - Integralife.com
    Collection: Plastic & Reconstructive Surgery · Composition: Native, Non-Denatured Bovine Dermis Collagen · Country of Origin: Made in USA · Finish: Flat, Dry Sheet ...
  35. [35]
    SurgiMend PRS Sterile Biologic Mesh
    SurgiMend PRS is a biologic mesh, also known as a dermal scaffold. Optimal handling characteristics. Hydrates in minutes; Easy to handle and place; Designed ...
  36. [36]
    Integra LifeSciences Completes the Acquisition of ACell, Inc.
    Jan 20, 2021 · “Acquiring ACell and its proprietary MatriStem UBM™ technologies will enable Integra to provide more comprehensive complex wound management ...
  37. [37]
    MicroMatrix® UBM Particulate - Integralife.com
    MicroMatrix offers a wound management solution for irregular, tunneled, or undermined wounds. Applied as either a powder or paste.<|separator|>
  38. [38]
    Gentrix® Surgical Matrix - Integra LifeSciences
    Gentrix Surgical Matrix is appropriate for the reinforcement of hiatal hernias, parastomal hernias and small ventral hernias in both laparoscopic and open ...
  39. [39]
    The Basics of Integra Dermal Regeneration Template and its ... - NIH
    Integra (Integra LifeSciences) is a synthetic acellular dermal regeneration template that provides a base for revascularization and neodermal formation.Missing: Harvard | Show results with:Harvard<|separator|>
  40. [40]
    A Comparison of SurgiMend PRS, AlloDerm, and DermACELL
    Jul 1, 2024 · Methods: A multicenter retrospective review of patients undergoing iPBR with SurgiMend PRS (fetal bovine-derived; Integra Lifesciences ...<|separator|>
  41. [41]
    Neurosurgery - Integra LifeSciences
    Our portfolio of neurosurgical solutions includes cranial stabilization and fixation systems, dural repair devices as well as electrosurgery and tissue ablation ...
  42. [42]
    DuraGen® Dural Graft Matrix - Integralife.com
    Made from Ultra Pure Collagen™, DuraGen® Dural Graft Matrix is an absorbable implant for repair of dural defects and the original onlay dural graft. Ordering ...
  43. [43]
    Durepair® Dura Regeneration Matrix - Integralife.com
    Designed to repair defects of the dura mater as a strong suturable dural graft (or as an onlay). Durepair provides users with an optimized combination of ...
  44. [44]
    CUSA® Clarity Handpiece - Integra LifeSciences
    The Power Handpiece (23 kHz) is designed for more challenging neurosurgical procedures including tough tissue and bone removal, as well as other specialties.
  45. [45]
    CUSA® Clarity 36 kHz Tips - Integra LifeSciences
    The CUSA Clarity Ultrasonic Surgical Aspirator is indicated for use in: Plastic and Reconstructive surgery, Orthopedic Surgery and Thoracic Surgery and the ...Missing: DuraGen | Show results with:DuraGen
  46. [46]
    https://products.integralife.com/cusa-clarity-handpiece/product/cusa-tissue-ablation-cusa-clarity-system-cusa-clarity-precision-handpiece
  47. [47]
    CODMAN® Ventricular Catheter - Integra LifeSciences
    We have a suite of surgical instrument offerings that are compatible with any hospital. View.Missing: irrigation systems management
  48. [48]
    Bactiseal® External Ventricular Drainage (EVD) Catheters
    Bactiseal® External Ventricular Drainage (EVD) Catheters are technically innovative anti-microbial impregnated catheters for external cerebrospinal fluid (CSF) ...Missing: irrigation | Show results with:irrigation
  49. [49]
    External CSF Drainage - Integra LifeSciences
    Cerebrospinal Fluid (CSF) Drainage Management System (1); Shunt Catheter (1) ... CODMAN® ACCU-FLO® Barium Ventricular Catheter. CODMAN ACCU-FLO Barium ...Missing: irrigation | Show results with:irrigation
  50. [50]
    Miltex® Instruments - Integra LifeSciences
    Miltex® Instruments,Discover Miltex, instruments made with quality German stainless steel that span across specialties and procedures.SurgicalDentalVeterinaryUrologicalOrthopedic
  51. [51]
    Integra® Miltex® Medical Supplies and Surgical Instruments ‌
    Miltex® Single Sterile Products · Miltex® Disposable Surgical Instruments · Miltex® Forceps · Miltex® Hemostats · Miltex® Surgical Scissors · Miltex®Needle Holders.
  52. [52]
    Ruggles®-Redmond™ - Products Integralife.com
    Ruggles®-Redmond™ · Access Instruments · BUZZ™ Bipolar Forceps · Curettes · Kerrisons · Microsurgery · Other Operating Instruments · Retractors · Rongeurs.Missing: portfolio Miltex Jarit
  53. [53]
    Surgical Instruments - Integralife.com
    Integra's surgical instruments are designed to perform a specific function, such as cutting, grasping, clamping, dissecting, probing, retracting, draining, ...Missing: RFS | Show results with:RFS
  54. [54]
    Balloon Sinuplasty - Integra LifeSciences
    Balloon Sinuplasty,Acclarent's Balloon Sinuplasty technology contributes to the sinus surgery evolution by offering a surgeon additional tools for ...
  55. [55]
    RELIEVA SPINPLUS® Balloon Sinuplasty System - Integralife.com
    The Balloon Sinuplasty System creates a durable opening and assists Otolaryngologists in achieving the goals of sinus surgery.1. Balloon Sinuplasty Benefits
  56. [56]
    Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
    Apr 1, 2024 · The company will release its first quarter 2024 financial results and provide second quarter and full-year guidance, inclusive of the Acclarent ...
  57. [57]
    Integra LifeSciences to Acquire Total Ankle Replacement (Salto ...
    Sep 3, 2015 · Integra LifeSciences to Acquire Total Ankle Replacement (Salto Talaris(R)) and Silastic Toe Replacement (Futura(TM)) Product Portfolios From ...Missing: system implants
  58. [58]
    Integra® Salto Talaris® Total Ankle - Adam Perler
    The Integra® Salto Talaris® Anatomic Ankle is a new generation ankle replacement that mimics the anatomy and flexion/extension movement of the natural ankle ...Missing: LifeSciences | Show results with:LifeSciences
  59. [59]
    Prospective Multicenter Study of Salto Talaris Ankle Arthroplasty ...
    Dec 27, 2023 · Treatment of end-stage ankle arthritis with this implant provided patients with improved pain and functional outcome scores at mid- to long-term follow-up.
  60. [60]
    List of 16 Acquisitions by Integra LifeSciences (Sep 2025) - Tracxn
    Sep 6, 2025 · Integra LifeSciences acquired it in December 2023 for a price of $275M. Here is the list of all acquisitions by Integra LifeSciences sorted by ...<|control11|><|separator|>
  61. [61]
    [PDF] Integra LIfeScIenceS OvervIew - AnnualReports.com
    Early in February 1996, Integra LifeSciences raised more than $35 million in a public offering, significantly strengthening our financial position.
  62. [62]
    Integra LifeSciences Completes the Acquisition of Codman ...
    Oct 2, 2017 · It has completed the previously announced acquisition of the Johnson & Johnson Codman Neurosurgery business for approximately $1.045 billion less customary ...
  63. [63]
    Integra LifeSciences Announces Definitive Agreement to Acquire ...
    Dec 16, 2020 · Integra LifeSciences announces definitive agreement to acquire ACell, Inc. PDF Version adds proprietary technology platform and complementary products.
  64. [64]
    Integra LifeSciences Reports Fourth Quarter and Full-Year 2017 ...
    Reported revenue for the full-year 2017 was $1,188.2 million, an increase of 19.8%, or $196.2 million over the prior year; acquisitions contributed $162.1 ...Missing: 2017-2019 | Show results with:2017-2019
  65. [65]
    Annual Report - SEC.gov
    Integra, headquartered in Plainsboro, New Jersey, is a world leader in medical technology. The Company was founded in 1989 with the acquisition of an ...
  66. [66]
    [PDF] Transforming For Growth - AnnualReports.com
    Feb 23, 2021 · Codman Specialty Surgical (CSS) reported revenue was $895 million, representing 9 percent organic growth, which was lower versus year ago ...
  67. [67]
    Integra LifeSciences Plans to Acquire the Codman Neurosurgery ...
    Feb 15, 2017 · It has made a binding offer to acquire the Johnson & Johnson Codman Neurosurgery business for a price of $1.045 billion in cash.
  68. [68]
    Integra LifeSciences Reports First Quarter 2025 Financial Results
    Total reported revenues of $382.7 million increased 3.7% on a reported basis and declined (3.5)% on an organic basis compared to the prior year.
  69. [69]
    Integra LifeSciences Corporation - 660960 - 07/17/2023 - FDA
    Aug 15, 2023 · Your firm is a medical device manufacturer of collagen based medical devices, that are used for wound care, soft tissue repair and reconstruction surgery, ...
  70. [70]
    Integra recalls all devices made at Boston facility in the past 5 years ...
    May 24, 2023 · The recall primarily affects tissue products, such as the SurgiMend collagen matrix, that account for 5% of the company's revenues. Integra ...
  71. [71]
    Integra LifeSciences Corporation - 698850 - 12/19/2024 - FDA
    Jan 14, 2025 · Integra LifeSciences Corporation, located at 11 Cabot Blvd, Mansfield, MA, FEI 3014334038, from March 12, 2024 through June 5, 2024; Integra ...<|control11|><|separator|>
  72. [72]
    [PDF] Form 8-K for Integra Lifesciences Holdings Corp filed 01/06/2025
    Jan 6, 2025 · The warning letter relates to quality system issues identified during FDA inspections at three of the Company's facilities located in ...
  73. [73]
    Class 2 Device Recall MediHoney Gel
    Feb 12, 2025 · The dressing helps maintain a moist environment conducive to wound healing and helps aid and support autolytic debridement. ... Integra ...Missing: remediation care
  74. [74]
    Applicator Recall: Integra LifeSciences Removes MicroMyst ... - FDA
    Jul 21, 2025 · Reason for Recall​​ Integra LifeSciences is recalling MicroMyst Applicators due to incomplete bioburden assessments and incomplete sterilization ...Missing: 2023 Boston
  75. [75]
    Integra LifeSciences Holdings C (IART) Q2 FY2025 earnings call ...
    Jul 31, 2025 · Integra LifeSciences reported Q2 2025 revenue of $415.6M, slightly down YoY but exceeding guidance, with adjusted EPS of $0.45 at the top ...
  76. [76]
    Integra still addressing problems at Boston plant | MedTech Dive
    May 8, 2024 · An inspection in 2023 led to a second warning letter, a recall and a temporary halt on manufacturing. The warning letter required Integra to ...
  77. [77]
    [PDF] Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 ...
    Feb 28, 2024 · In Q4 2023, reported revenue was $397.0M, down 0.2% (1.2% organic). Full-year 2023 revenue was $1,541.6M, down 1.0% (flat organic). GAAP EPS ...
  78. [78]
    Notice: SCAC Restructuring - Securities Class Action Clearinghouse
    On May 23, 2023, the Company announced a “recall” of all products manufactured at the Boston Facility between March 1, 2018 and May 22, 2023.Missing: fraud | Show results with:fraud
  79. [79]
    Why Integra LifeSciences Stock Is Crashing Today | The Motley Fool
    May 23, 2023 · Integra announced a global recall of products made at its Boston facility. · The company is also temporarily halting production at the facility.
  80. [80]
    Integra | Bernstein Litowitz Berger & Grossmann LLP
    Securities Fraud Litigation Corporate Governance & Shareholder Rights Distressed Debt & Bankruptcy Commercial Litigation Whistleblower Practice · Cases ...
  81. [81]
    Amid recalls, Minnesota medtech exec says she was pressured to ...
    Jan 30, 2025 · A lawsuit filed in US District Court in St. Paul alleges medtech firm Integra LifeSciences of New Jersey violated the Minnesota Whistleblower Act.
  82. [82]
    Amid recalls, Minnesota medtech exec says she was pressured to ...
    Jan 31, 2025 · A lawsuit filed in U.S. District Court in St. Paul alleges medtech firm Integra LifeSciences of New Jersey violated the Minnesota Whistleblower ...
  83. [83]
    Krause v. Integra LifeSciences Corporation, No. 0:2024cv04339
    Jul 11, 2025 · Court Description: ORDER denying 37 Motion to Transfer. (Written Opinion) Signed by Judge Laura M. Provinzino on 7/11/2025. (TJC).Missing: securities settlement
  84. [84]
    Integra Bosses Misled on FDA Warning Fix, Shareholder Suit Says
    May 14, 2025 · On July 29, Integra reduced its full-year 2024 financial guidance to account for shipping holds and compliance improvement across the company, ...
  85. [85]
    Kaskela Law LLC Announces Shareholder Investigation of Integra ...
    Sep 19, 2024 · https://kaskelalaw.com/case/integra-lifesciences/. Recently a securities fraud complaint was filed against Integra on behalf of investors who ...
  86. [86]
    grabar law office investigates claims on behalf of shareholders of ...
    An underlying securities fraud class action complaint alleges that the Company, via certain of his officers and directors, repeatedly touted that it was on ...
  87. [87]
    GRABOWSKY v. ANDERSON, 3:25-cv-01399 – CourtListener.com
    Feb 21, 2025 · District Court, D. New Jersey ... Last Updated: Aug. 12, 2025, 4:47 a.m. ... Citation: GRABOWSKY v. ANDERSON, 3:25-cv-01399, (D.N.J.) ... Items on ...
  88. [88]
    Integra Life Defeats Whistleblower's Federal Kickback Claims
    Aug 5, 2025 · Integra Life Sciences Corp. no longer has to defend itself against a whistleblower's claims that it defrauded federal health-care programs ...Missing: Minnesota | Show results with:Minnesota